Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment.
Actins
/ biosynthesis
Antineoplastic Agents
/ pharmacology
Apoptosis
Carcinoma
/ drug therapy
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
Cytoskeleton
/ drug effects
Drug Screening Assays, Antitumor
/ methods
Humans
Minerals
/ pharmacology
Resins, Plant
/ pharmacology
Tetrazolium Salts
/ analysis
Thiazoles
/ analysis
Urinary Bladder Neoplasms
/ drug therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 11 2021
19 11 2021
Historique:
received:
20
02
2021
accepted:
25
10
2021
entrez:
20
11
2021
pubmed:
21
11
2021
medline:
8
3
2022
Statut:
epublish
Résumé
Mumio (Shilajit) is a traditional medicinal drug known and used for hundreds of years. Bladder cancer is one of the most common cancer types and better treatments are needed. This study analysed the in vitro effect of Mumio on urinary bladder cancer cells (T24 and 5637) in comparison to normal uroepithelial cells (SV-HUC1). Cytotoxicity of Mumio was analysed in these cell lines via MTT and real-time cell growth assays as well via the assessment of the cytoskeleton, apoptosis, and cell cycle. Mumio affected the viability of both cell types in a time and concentration dependent manner. We observed a selectivity of Mumio against cancer cells. Cell cycle and apoptosis analysis showed that Mumio inhibited G0/G1 or S phase cell cycle, which in turn induced apoptosis. Our results showed that Mumio was significantly more cytotoxic to urinary bladder cancer cells than to normal cells. These results are promising and indicate Mumio as a great candidate for urinary bladder cancer treatment and further investigations should be performed.
Identifiants
pubmed: 34799663
doi: 10.1038/s41598-021-01996-8
pii: 10.1038/s41598-021-01996-8
pmc: PMC8604984
doi:
Substances chimiques
Actins
0
Antineoplastic Agents
0
Minerals
0
Resins, Plant
0
Tetrazolium Salts
0
Thiazoles
0
mumie
12633-76-0
thiazolyl blue
EUY85H477I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22614Informations de copyright
© 2021. The Author(s).
Références
J Exp Clin Cancer Res. 1998 Dec;17(4):431-4
pubmed: 10089063
BMC Complement Altern Med. 2016 May 27;16:148
pubmed: 27233240
Phytother Res. 2007 May;21(5):401-5
pubmed: 17295385
J Alzheimers Dis. 2011;27(1):143-53
pubmed: 21785188
Phytother Res. 2009 Mar;23(3):373-84
pubmed: 19107845
Food Chem Toxicol. 1999 Apr;37(4):313-8
pubmed: 10418948
Oncotarget. 2017 Oct 6;8(54):93279-93294
pubmed: 29190997
J Altern Complement Med. 2020 Jun;26(6):521-528
pubmed: 32310691
Evid Based Complement Alternat Med. 2011;2011:738131
pubmed: 18996940
J Ethnopharmacol. 2005 Oct 3;101(1-3):95-9
pubmed: 15878245
Pak J Pharm Sci. 2019 Sep;32(5):2167-2173
pubmed: 31813884
Lik Sprava. 1997 Nov-Dec;(6):129-32
pubmed: 9589956
Asian Pac J Trop Biomed. 2012 Mar;2(3):210-4
pubmed: 23569899
Int J Alzheimers Dis. 2012;2012:674142
pubmed: 22482077